YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
DENVER, September 24, 2026--(BUSINESS WIRE)--The Barron's 400 ETF (NYSE Arca: BFOR, the "Fund"), a smart beta exchange-traded fund, has completed its semi-annual rebalance following the reconstitution and equal weighting of its underlying…
On August 13, CorMedix (NASDAQ:CRMD) reported second quarter revenue of $101.9 million, more than double what it posted a year earlier, alongside net income of $26 million and adjusted EBITDA of $58.7 million, nearly triple the prior year'…
Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer - Joseph Todisco EVP and Chief Operating and Commercial Officer - Elizabeth Masson-Hurlburt EVP and Chief Fi…
CorMedix Therapeutics CRMD delivered second-quarter 2026 adjusted earnings of 29 cents per share, which increased 4% year over year from 28 cents reported in the year-ago quarter. The reported figure beat the Zacks Consensus Estimate of 26…
CorMedix Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Commercial Expansion Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick.…
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 CorMedix (NASDAQ:CRMD) reported second-quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, while reaffirming its full-year revenue outlook a…
PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13,…
[Stock market activity shows price changes and trading movements in real time] FabrikaCr As the market moves through second-quarter earnings season, investors are paying close attention to small-cap stocks that combine solid profitability…
Shares of Exelixis (EXEL) have been strong performers lately, with the stock up 7.7% over the past month. The stock hit a new 52-week high of $57.57 in the previous session. Exelixis has gained 30.2% since the start of the year compared to…
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied…
CorMedix CRMD is moving from a launch-driven story toward a broader test of commercial durability, portfolio integration and reimbursement execution. DefenCath remains the anchor, but the investment case now also includes Melinta assets, R…
CorMedix CRMD has become harder to dismiss after a sharp commercial turn. DefenCath is scaling, Melinta has broadened the sales base and profitability has improved. The question is whether that progress offsets a tougher second half of 202…
CorMedix CRMD has moved beyond a narrow launch story. DefenCath is now the core commercial engine, while the Melinta acquisition added a broader anti-infective platform and a longer-term Rezzayo opportunity. The investment debate is no lon…
Global biopharma executive and commercial strategist to lead the company's next chapter of growth CLEVELAND, June 22, 2026--(BUSINESS WIRE)--Within3, the leading Launch Intelligence™ platform for life sciences, today announced the appointm…
[Growth bar graph] Dougal Waters As U.S. corporate profit margins remain near historic highs, investors are increasingly looking for companies that can translate strong operating performance into sustained earnings growth. Recent data from…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Healthcare stocks have remained in focus as investors look for companies that can deliver strong operational growth w…
CorMedix Inc. (NASDAQ:CRMD) is one of the 10 Most Profitable Small Cap Stocks to Buy. On May 14, 2026, CorMedix Inc. (NASDAQ:CRMD) reported Q1 net revenue of $127.4 million and net income of $38.6 million with adjusted EBITDA of $70.0 mill…
CorMedix Therapeutics CRMD delivered first-quarter 2026 diluted earnings of 43 cents per share, up 43.3% year over year, beating the Zacks Consensus Estimate of 35 cents. Net revenue was $127.4 million, up significantly from the year-ago s…
CorMedix Inc. Q1 2026 Earnings Call Summary - Moby Strategic Performance and Market Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap…
Image source: The Motley Fool. DATE Thursday, May 14, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — Joseph Todisco Executive Vice President and Chief Operating Officer — Elizabeth Masson-Hurlburt Executive V…
Earnings Call Insights: CorMedix (CRMD) Q1 2026 MANAGEMENT VIEW * "CorMedix is entering 2026 with strong momentum across our core priorities, delivering durable DefenCath utilization growth, advancing high-value pipeline opportunities and…
medical research 3 ©Tima Miroshnichenko CorMedix Therapeutics (NASDAQ:CRMD) shares surged 8% in premarket trading Thursday after the company raised its full-year outlook despite reporting quarterly earnings slightly below analyst expectati…
Major earnings expected before the bell on Thursday include: * Canadian Solar (CSIQ [https://seekingalpha.com/symbol/CSIQ]) * Bullish (BLSH [https://seekingalpha.com/symbol/BLSH]) * Intuitive Machines (LUNR [https://seekingalpha.com/symbol…
(RTTNews) - CorMedix Inc. (CRMD), a biopharmaceutical company, announced financial results for the fourth quarter and full-year 2025 with revenue growth. In addition, the firm reaffirmed full-year 2026 guidance. For the fourth quarter, net…
Earnings Call Insights: CorMedix Inc. (CRMD) Q4 2025 MANAGEMENT VIEW * CEO Joseph Todisco stated that “2025 was truly a transformational year for CorMedix. While DefenCath achieved peak sales of just under $260 million, we are excited to h…
(RTTNews) - CorMedix Inc. (CRMD) released a profit for fourth quarter of $14.02 million The company's earnings totaled $14.02 million, or $0.16 per share. This compares with $13.47 million, or $0.20 per share, last year. The company's reve…
‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time…
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.33 per share, beating the Zacks Consensus Estimate of $1.99 per share. This compares to earnings of $1.63 per share a year ago. These figures are adjusted for non-recurring…
[Wall street sign on manhattan] franckreporter/iStock via Getty Images With the Q4 earnings season almost coming to an end, below is a list of small-cap stocks with positive quarterly EPS surprises ranked according to their lowest Seeking…
CorMedix CRMD and Theravance Biopharma TBPH occupy a similar niche in the market as small-cap biopharmaceutical companies working to turn promising science into sustainable revenues. Both companies, having a market cap of less than $1 bill…
We expect investors to focus on the sales performance of CorMedix’s CRMD lead product, DefenCath (taurolidine plus heparin), when the company reports fourth-quarter and full-year 2025 results. The Zacks Consensus Estimate for sales and ear…
Shares of CorMedix CRMD have witnessed a sharp decline over the past three months. A key reason for the stocks’ decline during this time has been the company’s bearish 2026 financial outlook. In January, management announced its 2026 guida…
We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy. CorMedix Inc. (NASDAQ:CRMD) announced that its board approved a share repurchase program authorizing up to $75 million in common stock buybacks, with the p…
The majority of CorMedix’s CRMD revenues come from its lead product, DefenCath, which is approved as the first and only antimicrobial catheter lock solution in the United States. The product is indicated to reduce the incidence of catheter…
[Stock exchange building columns stock market finance] alexsl Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next wee…
We recently compiled a list of the 9 High Growth Small Cap Stocks That Are Profitable. CorMedix Inc. tops our list for being one of the high growth stocks. TheFly reported on January 23 that H.C. Wainwright lowered the price target on CRMD…